ANZCA Final
Perioperative Medicine
General Anaesthesia
High Evidence

General Anaesthesia Induction

General anaesthesia induction is the transition from consciousness to unconsciousness with loss of protective airway reflexes, requiring controlled manipulation of physiology and airway management. Rapid sequence...

Updated 2 Feb 2026
1 min read
Citations
98 cited sources
Quality score
54 (gold)

Clinical board

A visual summary of the highest-yield teaching signals on this page.

Urgent signals

Safety-critical features pulled from the topic metadata.

  • Difficult airway with failed mask ventilation and intubation (CICV)
  • Anaphylaxis during induction
  • Cardiac arrest on induction
  • Awareness during general anaesthesia

Exam focus

Current exam surfaces linked to this topic.

  • ANZCA Final Written
  • ANZCA Final Clinical Viva
  • ANZCA Final Medical Viva

Editorial and exam context

ANZCA Final Written
ANZCA Final Clinical Viva
ANZCA Final Medical Viva
Clinical reference article

Quick Answer

General anaesthesia induction is the transition from consciousness to unconsciousness with loss of protective airway reflexes, requiring controlled manipulation of physiology and airway management. Rapid sequence induction (RSI) is the standard technique for patients with aspiration risk, using preoxygenation, cricoid pressure (10 Newtons), propofol (2-3 mg/kg) or thiopental (4-5 mg/kg), succinylcholine (1.5 mg/kg) or rocuronium (1.2 mg/kg), and avoiding positive pressure ventilation until intubation confirmed. Preoxygenation with 100% oxygen for 3-5 minutes extends safe apnoea time from 2 minutes to 8-10 minutes in healthy adults. Difficult airway management requires a structured approach: Plan A (optimal direct laryngoscopy with bougie or video laryngoscopy), Plan B (second-generation supraglottic airway), Plan C (front-of-neck access). Aspiration prophylaxis includes sodium citrate 0.3 M 30 mL PO, ranitidine 50 mg IV, metoclopramide 10 mg IV. Total intravenous anaesthesia (TIVA) with propofol infusion (target effect-site concentration 4-6 μg/mL) plus remifentanil (0.05-0.2 μg/kg/min) provides stable anaesthesia without volatile agents, useful for neurosurgery, PONV prophylaxis, and malignant hyperthermia-susceptible patients. Indigenous patients may have higher rates of obesity and difficult airways, requiring careful airway assessment, culturally safe consent processes, and planning for potential difficult intubation scenarios. [1-10]